Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Oct 11, 2024 10:13am
131 Views
Post# 36262535

RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer

RE:Pelareorep in 3rd line HR+/HER2 negative breast cancerOctober 11, 2024 - Roche's drug, inavolisib, has gained FDA approval as part of a first-line treatment for HR-positive, HER2-negative breast cancer that has a PIK3CA mutation and is resistant to adjuvant endocrine therapy. The oral med is to be used in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex. 

Itovebi is part of a bigger pipeline that Roche hopes could rejuvenate its breast cancer business. The company’s once flagship HER2 franchise lost some of its luster after Herceptin fell off the patent cliff and Kadcyla comes under pressure from AZ and Daiichi Sankyo’s star antibody-drug conjugate Enhertu.

Besides Itovebi, Roche is advancing the oral SERD drug giredestrant in HR+/HER2- breast cancer, with key phase 3 readouts expected in 2025.


Last week, Roche announced a $850 million upfront deal with Regor Pharmaceuticals, adding an early-stage CDK4/2 inhibitor and a phase 1-ready CDK4 drug to its portfolio.


https://www.fiercepharma.com/pharma/roche-burnishes-breast-cancer-portfolio-fda-approval-itovebi-threat-novartis-and-az
<< Previous
Bullboard Posts
Next >>